Artificial Tears: A Systematic Review

References

• Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocular Surface. 2017;15(3):575–628. doi:10.1016/j.jtos.2017.05.006
   PubMed Web of Science ®Google Scholar
• Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev. 2016;2016(2):Cd009729. doi:10.1002/14651858.CD009729.pub2
   Google Scholar
• Essa L, Laughton D, Wolffsohn JS. Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs and symptoms? Contact Lens Anterior Eye. 2018;41(1):60–68. doi:10.1016/j.clae.2017.07.007
   PubMed Web of Science ®Google Scholar
• Craig JP, Muntz A, Wang MTM, et al. Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: a six-month multicentre, double-masked randomised controlled trial. Ocular Surface. 2021;20:62–69. doi:10.1016/j.jtos.2020.12.006
   PubMed Web of Science ®Google Scholar
• Hynnekleiv L, Magno M, Vernhardsdottir RR, et al. Hyaluronic acid in the treatment of dry eye disease. Acta Ophthalmol. 2022;100:844–860. doi:10.1111/aos.15159
   PubMed Web of Science ®Google Scholar
• Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. Ocular Surface. 2017;15(3):511–538. doi:10.1016/j.jtos.2017.05.004
   PubMed Web of Science ®Google Scholar
• Dietlein TS, Jordan JF, Lüke C, Schild A, Dinslage S, Krieglstein GK. Self‐application of single‐use eyedrop containers in an elderly population: comparisons with standard eyedrop bottle and with younger patients. Acta Ophthalmologica. 2008;86(8):856–859. doi:10.1111/j.1755-3768.2007.01155.x
   PubMed Web of Science ®Google Scholar
• Connor A, Severn P. Force requirements in topical medicine use—the squeezability factor. Eye. 2011;25(4):466–469. doi:10.1038/eye.2011.5
   PubMed Web of Science ®Google Scholar
• Drew T, Wolffsohn JS. Usability of prostaglandin monotherapy eye droppers. Br J Ophthalmol. 2015;99(9):1251–1254. doi:10.1136/bjophthalmol-2014-306291
   Web of Science ®Google Scholar
• Kashiwagi K. Wide variation of squeezing force and dispensing time interval among eyedropper bottles. J Ophthalmol. 2019:2019:115.
   Web of Science ®Google Scholar
• NHS. Why can’t I get a prescription for an over-the-counter medicine? NHS. Available from: https://www.nhs.uk/common-health-questions/medicines/why-cant-i-get-prescription-over-counter-medicine/. Accessed September 6, 2022.
   Google Scholar
• Bilkhu P, Sivardeen Z, Chen C, et al. Patient-reported experience of dry eye management: an international multicentre survey. Cont Lens Anterior Eye. 2022;45(1):101450. doi:10.1016/j.clae.2021.101450
   Web of Science ®Google Scholar
• Lee S-Y, Tong L. Lipid-containing lubricants for dry eye: a systematic review. Optomet Vision Sci. 2012;89(11):1654–1661. doi:10.1097/OPX.0b013e31826f32e0
   PubMed Web of Science ®Google Scholar
• Moshirfar M, Pierson K, Hanamaikai K, Santiago-Caban L, Muthappan V, Passi SF. Artificial tears potpourri: a literature review. Clin Ophthalmol. 2014;8:1419. doi:10.2147/OPTH.S65263
   PubMedGoogle Scholar
• Agarwal P, Khun D, Krösser S, et al. Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics. Ocul Surf. 2019;17(2):241–249. doi:10.1016/j.jtos.2019.02.010
   Web of Science ®Google Scholar
• Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retinal Eye Res. 2010;29(4):312–334. doi:10.1016/j.preteyeres.2010.03.001
   PubMed Web of Science ®Google Scholar
• Kathuria A, Shamloo K, Jhanji V, Sharma A. Categorization of marketed artificial tear formulations based on their ingredients: a rational approach for their use. J Clin Med. 2021;10(6):1289. doi:10.3390/jcm10061289
   PubMed Web of Science ®Google Scholar
• Pisárčik M, Bakoš D, Čeppan MJC, et al. Non-Newtonian properties of hyaluronic acid aqueous solution. Am J Phys Anthropol. 1995;97(3):197–202. doi:10.1002/ajpa.1330970209
   Google Scholar
• Arshinoff SA, Hofmann I, Nae H, Surgery R. Role of rheology in tears and artificial tears. J Cataract Refract Surg. 2021;47(5):655–661.
   PubMed Web of Science ®Google Scholar
• Rah MJ. A review of hyaluronan and its ophthalmic applications. Optomet-J Am Optometr Assoc. 2011;82(1):38–43. doi:10.1016/j.optm.2010.08.003
   PubMedGoogle Scholar
• Balazs E, Freeman M, Klöti R, Meyer-Schwickerath G, Regnault F, Sweeney D. Hyaluronic acid and replacement of vitreous and aqueous humor. Mod Probl Ophthalmol. 1972;10:3–21.
   PubMedGoogle Scholar
• Polack FM, McNiece M. The treatment of dry eyes with Na hyaluronate (Healon®). Cornea. 1982;1(2):133–136. doi:10.1097/00003226-198201020-00007
   Google Scholar
• Müller-Lierheim WG. Why chain length of hyaluronan in eye drops matters. Diagnostics. 2020;10(8):511. doi:10.3390/diagnostics10080511
   Web of Science ®Google Scholar
• Kojima T, Nagata T, Kudo H, et al. The effects of high molecular weight hyaluronic acid eye drop application in environmental dry eye stress model mice. Int J Mol Sci. 2020;21(10):3516. doi:10.3390/ijms21103516
   Web of Science ®Google Scholar
• Pauloin T, Dutot M, Warnet J-M, Rat P. In vitro modulation of preservative toxicity: high molecular weight hyaluronan decreases apoptosis and oxidative stress induced by benzalkonium chloride. Eur J Pharma Sci. 2008;34(4–5):263–273. doi:10.1016/j.ejps.2008.04.006
   Web of Science ®Google Scholar
• Pauloin T, Dutot M, Joly F, Warnet J-M, Rat P. High molecular weight hyaluronan decreases UVB-induced apoptosis and inflammation in human epithelial corneal cells. Molecular Vision. 2009;15:577.
   PubMed Web of Science ®Google Scholar
• Wu CL, Chou HC, Li JM, et al. Hyaluronic acid‐dependent protection against alkali‐burned human corneal cells. Electrophoresis. 2013;34(3):388–396. doi:10.1002/elps.201200342
   Web of Science ®Google Scholar
• Gomis A, Pawlak M, Balazs EA, Schmidt RF, Belmonte CJA. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthrit Rheumat. 2004;50(1):314–326. doi:10.1002/art.11421
   PubMedGoogle Scholar
• Song JK, Lee K, Park HY, et al. Efficacy of carboxymethylcellulose and hyaluronate in dry eye disease: a systematic review and meta-analysis. Korean J Fam Med. 2017;38(1):2–7. doi:10.4082/kjfm.2017.38.1.2
   Google Scholar
• Ang BCH, Sng JJ, Wang PXH, Htoon HM, Tong LHT. Sodium hyaluronate in the treatment of dry eye syndrome: a systematic review and meta-analysis. Sci Rep. 2017;79013. doi:10.1038/s41598-017-08534-5
   Web of Science ®Google Scholar
• Alves M, Fonseca EC, Alves MF, et al. Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies. Ocul Surf. 2013;11(3):181–192. doi:10.1016/j.jtos.2013.02.002
   PubMed Web of Science ®Google Scholar
• Liu R, Rong B, Tu P, et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. Am J Ophthalmol. 2017;183:81–90. doi:10.1016/j.ajo.2017.08.021
   PubMed Web of Science ®Google Scholar
• Yang YJ, Lee WY, Kim YJ, Hong YP. A meta-analysis of the efficacy of hyaluronic acid eye drops for the treatment of dry eye syndrome. Int J Environ Res Public Health. 2021;18(5). doi:10.3390/ijerph18052383
   Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol. 2021;74(9):790–799. doi:10.1016/j.rec.2021.07.010
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928
   PubMed Web of Science ®Google Scholar
• Lemp MA, Foulks GN. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75–92. doi:10.1016/s1542-0124(12)70081-2
   PubMed Web of Science ®Google Scholar
• Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539–574. doi:10.1016/j.jtos.2017.05.001
   PubMed Web of Science ®Google Scholar
• Armstrong RA. Statistical guidelines for the analysis of data obtained from one or both eyes. Ophthalmic Physiol Opt. 2013;33(1):7–14. doi:10.1111/opo.12009
   PubMed Web of Science ®Google Scholar
• Sanchez MA, Torralbo-Jimenez P, Giron N, et al. Comparative analysis of carmellose 0.5% versus hyaluronate 0.15% in dry eye: a flow cytometric study. Cornea. 2010;29(2):167–171. doi:10.1097/ICO.0b013e3181b11648
   PubMed Web of Science ®Google Scholar
• Brignole F, Pisella PJ, Dupas B, Baeyens V, Baudouin C. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch Clin Exp Ophthalmol. 2005;243(6):531–538. doi:10.1007/s00417-004-1040-6
   PubMed Web of Science ®Google Scholar
• Calvao-Santos G, Borges C, Nunes S, Salgado-Borges J, Duarte L. Efficacy of 3 different artificial tears for the treatment of dry eye in frequent computer users and/or contact lens users. Eur J Ophthalmol. 2011;21(5):538–544. doi:10.5301/ejo.2011.6324
   PubMed Web of Science ®Google Scholar
• Pinto-Bonilla JC, Del Olmo-Jimeno A, Llovet-Osuna F, Hernandez-Galilea E. A randomized crossover study comparing trehalose/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome. Ther Clin Risk Manag. 2015;11:595–603. doi:10.2147/TCRM.S77091
   PubMed Web of Science ®Google Scholar
• Mihaltz K, Faschinger EM, Vecsei-Marlovits PV. Effects of lipid- versus sodium hyaluronate-containing eye drops on optical quality and ocular surface parameters as a function of the meibomian gland dropout rate. Cornea. 2018;37(7):886–892. doi:10.1097/ico.0000000000001523
   PubMed Web of Science ®Google Scholar
• Peterson RC, Wolffsohn JS, Fowler CW. Optimization of anterior eye fluorescein viewing. Am J Ophthalmol. 2006;142(4):572–575. doi:10.1016/j.ajo.2006.04.062
   Web of Science ®Google Scholar
• Delaveris A, Stahl U, Madigan M, Jalbert I. Comparative performance of lissamine green stains. Cont Lens Anterior Eye. 2018;41(1):23–27. doi:10.1016/j.clae.2017.11.002
   Web of Science ®Google Scholar
• Troiano P, Monaco G. Effect of hypotonic 0.4% hyaluronic acid drops in dry eye patients: a cross-over study. Cornea. 2008;27(10):1126–1130. doi:10.1097/ICO.0b013e318180e55c
   PubMed Web of Science ®Google Scholar
• Perez-Balbuena AL, Ochoa-Tabares JC, Belalcazar-Rey S, et al. Efficacy of a fixed combination of 0.09 % xanthan gum/0.1 % chondroitin sulfate preservative free vs polyethylene glycol/propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial. BMC Ophthalmol. 2016;16164. doi:10.1186/s12886-016-0343-9
   Web of Science ®Google Scholar
• Aragona P, Benitez-del-Castillo JM, Coroneo MT, et al. Safety and efficacy of a preservative-free artificial tear containing carboxymethylcellulose and hyaluronic acid for dry eye disease: a randomized, controlled, multicenter 3-month study. Clin Ophthalmol. 2020;14:2951–2963. doi:10.2147/opth.S256480
   Web of Science ®Google Scholar
• Simmons PA, Liu H, Carlisle-Wilcox C, Vehige JG. Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial. Clin Ophthalmol. 2015;9:665–675. doi:10.2147/opth.S78184
   PubMed Web of Science ®Google Scholar
• Chiambaretta F, Doan S, Labetoulle M, et al. A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome. Eur J Ophthalmol. 2017;27(1):1–9. doi:10.5301/ejo.5000836
   Web of Science ®Google Scholar
• Schmidl D, Schmetterer L, Witkowska KJ, et al. Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease. Cornea. 2015;34(4):421–426. doi:10.1097/ICO.0000000000000358
   PubMed Web of Science ®Google Scholar
• Lievens C, Berdy G, Douglass D, et al. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: a multicenter, double-masked, randomized 30-day study. Contact Lens Anterior Eye. 2019;42(4):443–449. doi:10.1016/j.clae.2018.12.003
   PubMed Web of Science ®Google Scholar
• Postorino EI, Rania L, Aragona E, et al. Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye. Eur J Ophthalmol. 2018;28(1):25–31. doi:10.5301/ejo.5001011
   PubMed Web of Science ®Google Scholar
• Gokul A, Wang MTM, Craig JP. Tear lipid supplement prophylaxis against dry eye in adverse environments. Contact Lens Anterior Eye. 2018;41(1):97–100. doi:10.1016/j.clae.2017.09.013
   Web of Science ®Google Scholar
• Muntz A, Marasini S, Wang MTM, Craig JP. Prophylactic action of lipid and non-lipid tear supplements in adverse environmental conditions: a randomised crossover trial. Ocular Surface. 2020;18(4):920–925. doi:10.1016/j.jtos.2020.08.004
   Web of Science ®Google Scholar
• Johnson ME, Murphy PJ, Boulton M. Carbomer and sodium hyaluronate eyedrops for moderate dry eye treatment. Optomet Vision Sci. 2008;85(8):750–757. doi:10.1097/OPX.0b013e318182476c
   PubMed Web of Science ®Google Scholar
• Baudouin C, Cochener B, Pisella PJ, et al. Randomized, Phase III study comparing osmoprotective carboxymethylcellulose with sodium hyaluronate in dry eye disease. Eur J Ophthalmol. 2012;22(5):751–761. doi:10.5301/ejo.5000117
   PubMed Web of Science ®Google Scholar
• Lee JH, Ahn HS, Kim EK, Kim T-I. Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea. 2011;30(2):175–179. doi:10.1097/ICO.0b013e3181e9adcc
   PubMed Web of Science ®Google Scholar
• Park Y, Song JS, Choi CY, et al. A randomized multicenter study comparing 0.1%, 0.15%, and 0.3% sodium hyaluronate with 0.05% cyclosporine in the treatment of dry eye. J Ocular Pharmacol Therap. 2017;33(2):66–72.
   Web of Science ®Google Scholar
• Johnson ME, Murphy PJ, Boulton M. Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye. Graefes Arch Clin Exp Ophthalmol. 2006;244(1):109–112. doi:10.1007/s00417-005-0028-1
   PubMed Web of Science ®Google Scholar
• Christensen MT, Cohen S, Rinehart J, et al. Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye. Curr Eye Res. 2004;28(1):55–62. doi:10.1076/ceyr.28.1.55.23495
   Web of Science ®Google Scholar
• Benelli U, Nardi M, Posarelli C, Albert TG. Tear osmolarity measurement using the TearLab™ Osmolarity System in the assessment of dry eye treatment effectiveness. Contact Lens Anterior Eye. 2010;33(2):61–67. doi:10.1016/j.clae.2010.01.003
   PubMed Web of Science ®Google Scholar
• Cohen S, Martin A, Sall K. Evaluation of clinical outcomes in patients with dry eye disease using lubricant eye drops containing polyethylene glycol or carboxymethylcellulose. Clin Ophthalmol. 2014;8:157–164. doi:10.2147/opth.S53822
   PubMedGoogle Scholar
• Davitt WF, Bloomenstein M, Christensen M, Martin AE. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation. J Ocular Pharmacol Therap. 2010;26(4):347–353. doi:10.1089/jop.2010.0025
   PubMed Web of Science ®Google Scholar
• Ousler GW, Michaelson C, Christensen MT. An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops. Cornea. 2007;26(8):949–952. doi:10.1097/ICO.0b013e3180de1c38
   PubMed Web of Science ®Google Scholar
• Grene RB, Lankston P, Mordaunt J, Harrold M, Gwon A, Jones R. Unpreserved carboxymethylcellulose artificial tears evaluated in patients with keratoconjunctivities sicca. Cornea. 1992;11(4):294–301. doi:10.1097/00003226-199207000-00004
   PubMed Web of Science ®Google Scholar
• Garcia-Lazaro S, Belda-Salmeron L, Ferrer-Blasco T, Cervino A, Montes-Mico R. Comparison of two artificial tear formulations for dry eye through high-resolution optical coherence tomography. Clin Exp Optomet. 2011;94(6):549–556. doi:10.1111/j.1444-0938.2011.00632.x
   Web of Science ®Google Scholar
• Robert PY, Cochener B, Amrane M, et al. Efficacy and safety of a cationic emulsion in the treatment of moderate to severe dry eye disease: a randomized controlled study. Eur J Ophthalmol. 2016;26(6):546–555. doi:10.5301/ejo.5000830
   PubMed Web of Science ®Google Scholar
• Amrane M, Creuzot-Garcher C, Robert PY, et al. Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease - A randomised comparative study. J Francais D Ophtalmologie. 2014;37(8):589–598. doi:10.1016/j.jfo.2014.05.001
   PubMed Web of Science ®Google Scholar
• Iester M, Orsoni GJ, Gamba G, et al. Improvement of the ocular surface using hypotonic 0.4% hyaluronic acid drops in keratoconjunctivitis sicca. Eye. 2000;14(6):892–898. doi:10.1038/eye.2000.244
   PubMedGoogle Scholar
• Marner K, Moller PM, Dillon M, RaskPedersen E. Viscous carbomer eye drops in patients with dry eyes - Efficacy and safety. A randomized, open, cross-over, multicentre study. Acta Ophthalmologica Scandinavica. 1996;74(3):249–252. doi:10.1111/j.1600-0420.1996.tb00086.x
   Google Scholar
• Xiao Q, Hu Y, Chen F, Chen X. A comparative assessment of the efficacy of carbomer gel and carboxymethyl cellulose containing artificial tears in dry eyes. J Huazhong Univ Sci Technol. 2008;28(5):592–595. doi:10.1007/s11596-008-0523-9
   Google Scholar
• Wang IJ, Lin IC, Hou YC, Hu FR. A comparison of the effect of carbomer-, cellulose-, and mineral oil-based artificial tear formulations. Eur J Ophthalmol. 2007;17(2):151–159. doi:10.1177/112067210701700202
   PubMed Web of Science ®Google Scholar
• Baeyens V, Bron A, Baudouin C; Vismed Hylovis Study Group. Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease. J Francais D Ophtalmologie. 2012;35(6):412–419. doi:10.1016/j.jfo.2011.07.017
   PubMed Web of Science ®Google Scholar
• Asbell P, Vingrys AJ, Tan J, et al. Clinical outcomes of fixed versus as-needed use of artificial tears in dry eye disease: a 6-week, observer-masked phase 4 clinical trial. Invest Ophthalmol Vis Sci. 2018;59(6):2275–2280. doi:10.1167/iovs.17-23733
   PubMed Web of Science ®Google Scholar
• Dausch D, Lee S, Dausch S, Kim JC, Schwert G, Michelson W. Comparative study of treatment of the dry eye syndrome due to disturbances of the tear film lipid layer with lipid-containing tear substitutes - efficacy of lipid-containing tear substitutes. Klin Monbl Augenheilkd. 2006;223(12):974–983. doi:10.1055/s-2006-927266
   PubMed Web of Science ®Google Scholar
• Pult H, Khatum FS, Trave-Huarte S, Wolffsohn JS. Effect of eye spray phospholipid concentration on the tear film and ocular comfort. Eye Contact Lens-Sci Clin Pract. 2021;47(8):445–448. doi:10.1097/icl.0000000000000788
   Web of Science ®Google Scholar
• Simmons PA, Vehige JG. Clinical performance of a mid-viscosity artificial tear for dry eye treatment. Cornea. 2007;26(3):294–302. doi:10.1097/ICO.0b013e31802e1e04
   PubMed Web of Science ®Google Scholar
• Simmons PA, Carlisle-Wilcox C, Vehige JG. Comparison of novel lipid-based eye drops with aqueous eye drops for dry eye: a multicenter, randomized controlled trial. Clin Ophthalmol. 2015;9:657–664. doi:10.2147/opth.S74849
   Google Scholar
• Röggla V, Leydolt C, Schartmüller D, et al. Influence of artificial tears on keratometric measurements in cataract patients. Am J Ophthalmol. 2021;221:1–8. doi:10.1016/j.ajo.2020.08.024
   PubMed Web of Science ®Google Scholar
• Prinz J, Mehta JS, Walter P, Fuest M. Simple limbal epithelial transplantation (SLET) A simple technique for the treatment of unilateral complete limbal stem cell deficiency. Video article. Ophthalmologe. 2021;118(4):404–412. doi:10.1007/s00347-021-01346-z
   Web of Science ®Google Scholar
• Walsh K, Jones L. The use of preservatives in dry eye drops. Clin Ophthalmol. 2019;13:1409–1425. doi:10.2147/opth.S211611
   PubMed Web of Science ®Google Scholar
• Segal KL, Fleischut P, Kim C, et al. Evaluation and treatment of perioperative corneal abrasions. J Ophthalmol. 2014;2014:901901. doi:10.1155/2014/901901
   Web of Science ®Google Scholar
• Lozano JS, Chay EY, Healey J, Sullenberger R, Klarlund JK. Activation of the epidermal growth factor receptor by hydrogels in artificial tears. Exp Eye Res. 2008;86(3):500–505. doi:10.1016/j.exer.2007.12.003
   Web of Science ®Google Scholar
• Salama A, Elsheikh A, Alweis R. Is this a worrisome red eye? Episcleritis in the primary care setting. J Commun Hosp Intern Med Perspect. 2018;8(1):46–48. doi:10.1080/20009666.2017.1418110
   PubMed Web of Science ®Google Scholar
• Williams CPR, Browning AC, Sleep TJ, Webber SK, McGill JI. A randomised, double-blind trial of topical ketorolac vs artificial tears for the treatment of episcleritis. EYE. 2005;19(7):739–742. doi:10.1038/sj.eye.6701632
   Web of Science ®Google Scholar
• Mohammadpour M, Khorrami-Nejad M, Shakoor D. Role of artificial tears with and without hyaluronic acid in controlling ocular discomfort following PRK: a randomized clinical trial. Int J Ophthalmol. 2021;14(8):1225–1230. doi:10.18240/ijo.2021.08.14
   Web of Science ®Google Scholar
• Fujishima H, Yagi Y, Shimazaki J, Tsubota K. Effects of artificial tear temperature on corneal sensation and subjective comfort. Cornea. 1997;16(6):630–634. doi:10.1097/00003226-199711000-00005
   Web of Science ®Google Scholar
• Bitton E, Crncich V, Brunet N. Does the temperature of an artificial tear affect its comfort? Clin Exp Optomet. 2018;101(5):641–647. doi:10.1111/cxo.12664
   Web of Science ®Google Scholar
• Galor A, Batawi H, Felix ER, et al. Incomplete response to artificial tears is associated with features of neuropathic ocular pain. Br J Ophthalmol. 2016;100(6):745–749. doi:10.1136/bjophthalmol-2015-307094
   PubMed Web of Science ®Google Scholar
• Kim M, Lee Y, Mehra D, Sabater AL, Galor A. Dry eye: why artificial tears are not always the answer. BMJ Open Ophthalmol. 2021;6(1):e000697. doi:10.1136/bmjophth-2020-000697
   Web of Science ®Google Scholar
• Bilkhu PS, Wolffsohn JS, Naroo SA, Robertson L, Kennedy R. Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. Ophthalmology. 2014;121(1):72–78. doi:10.1016/j.ophtha.2013.08.007
   PubMed Web of Science ®Google Scholar
• Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015;(6):Cd009566. doi:10.1002/14651858.CD009566.pub2
   PubMed Web of Science ®Google Scholar
• Shiuey Y, Ambati BK, Adamis AP; Viral Conjunctivitis Study Group. A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis. Ophthalmology. 2000;107(8):1512–1517. doi:10.1016/S0161-6420(00)00177-9
   Web of Science ®Google Scholar
• Lyra AFV, Bastos LC, Lima RCD, Maranhao LDL, Arantes TE. Artificial tears alone versus 0.45% ketorolac tromethamine with artificial tears for the treatment of acute viral conjunctivitis. Arq Bras Oftalmol. 2014;77(2):99–102. doi:10.5935/0004-2749.20140025
   Web of Science ®Google Scholar
• Santiago LA, da Silva JMR, de Azevedo OGR, de Vasconcelos PRL. Comparative study on the efficacy of non-steroidal, steroid and non-use of anti-inflammatory in the treatment of acute epidemic conjunctivitis. Acta Cirurgica Brasileira. 2019;34(12):e201901206. doi:10.1590/s0102-865020190120000006
   Web of Science ®Google Scholar
• Messmer EM. [Bacterial conjunctivitis--diagnosis and therapy update] Bakterielle Konjunktivitis--Update zu Diagnose und Therapie. Klin Monbl Augenheilkd. 2012;229(5):529–533. doi:10.1055/s-0031-1299523
   Google Scholar
• Sengillo JD, Kunkler AL, Medert C, et al. UV-photokeratitis associated with germicidal lamps purchased during the COVID-19 pandemic. Ocul Immunol Inflamm. 2021;29(1):76–80. doi:10.1080/09273948.2020.1834587
   PubMed Web of Science ®Google Scholar
• Choy CKM, Cho P, Boost MV. Cytotoxicity of rigid gas-permeable lens care solutions. Clin Exp Optomet. 2013;96(5):467–471. doi:10.1111/cxo.12039
   Web of Science ®Google Scholar
• Pucker AD. A review of the compatibility of topical artificial tears and rewetting drops with contact lenses. Contact Lens Anterior Eye. 2020;43(5):426–432. doi:10.1016/j.clae.2020.04.013
   Web of Science ®Google Scholar
• Pucker AD, McGwin G, Franklin QX, Dubey J, Nattis A, Lievens C. Application of systane complete for the treatment of contact lens discomfort. Contact Lens Anterior Eye. 2021;44(4):101399. doi:10.1016/j.clae.2020.12.004
   Web of Science ®Google Scholar
• Chou H-D, Chen K-J, Kang EY-C, et al. Eye irrigation as a first-line treatment and diagnostic method for emergency department patients who complain of ocular foreign bodies. Sci Rep. 2021;11(1):23386. doi:10.1038/s41598-021-02989-3
   Web of Science ®Google Scholar
• NICE. Corneal superficial injury. Available from: https://cks.nice.org.uk/topics/corneal-superficial-injury/. Accessed July 20, 2022.
   Google Scholar
• Barabino S, Rolando M, Nardi M, Bonini S, Aragona P, Traverso CE. The effect of an artificial tear combining hyaluronic acid and tamarind seeds polysaccharide in patients with moderate dry eye syndrome: a new treatment for dry eye. Eur J Ophthalmol. 2014;24(2):173–178. doi:10.5301/ejo.5000355
   PubMed Web of Science ®Google Scholar
• Brodwall J, Alme G, Gedde‐Dahl S, et al. A comparative study of polyacrylic acid (Viscotears®) liquid gel versus polyvinylalcohol in the treatment of dry eyes. Acta Ophthalmologica Scandinavica. 1997;75(4):457–461. doi:10.1111/j.1600-0420.1997.tb00413.x
   PubMedGoogle Scholar
• Bron A, Daubas P, Siou-Mermet R, Trinquand C. Comparison of the efficacy and safety of two eye gels in the treatment of dry eyes: lacrinorm and viscotears. Eye. 1998;12(5):839–847. doi:10.1038/eye.1998.215
   Google Scholar
• Comez AT, Tufan HA, Kocabiyik O, Gencer B. Effects of lubricating agents with different osmolalities on tear osmolarity and other tear function tests in patients with dry eye. Curr Eye Res. 2013;38(11):1095–1103. doi:10.3109/02713683.2013.806670
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, Dolores Pinazo-Duran M, Diaz-Guinon L, et al. A randomized multicenter study comparing seawater washes and carmellose artificial tears eyedrops in the treatment of dry eye syndrome. Clin Ophthalmol. 2019;13:483–490. doi:10.2147/opth.S185409
   Web of Science ®Google Scholar
• Downie LE, Hom MM, Berdy GJ, et al. An artificial tear containing flaxseed oil for treating dry eye disease: a randomized controlled trial. Ocul Surf. 2020;18(1):148–157. doi:10.1016/j.jtos.2019.11.004
   PubMed Web of Science ®Google Scholar
• Dumbleton K, Woods C, Fonn D. An investigation of the efficacy of a novel ocular lubricant. Eye Contact Lens-Sci Clin Pract. 2009;35(3):149–155. doi:10.1097/ICL.0b013e3181a2c986
   Web of Science ®Google Scholar
• Fogt JS, Fogt N, King-Smith PE, Liu HX, Barr JT. Changes in tear lipid layer thickness and symptoms following the use of artificial tears with and without omega-3 fatty acids: a randomized, double-masked, crossover study. Clin Ophthalmol. 2019;13:2553–2561. doi:10.2147/OPTH.S228261
   Web of Science ®Google Scholar
• Fondi K, Wozniak PA, Schmidl D, et al. Effect of hyaluronic acid/trehalose in two different formulations on signs and symptoms in patients with moderate to severe dry eye disease. J Ophthalmol. 2018;2018:20184691417. doi:10.1155/2018/4691417
   Web of Science ®Google Scholar
• Gensheimer WG, Kleinman DM, Gonzalez MO, et al. Novel formulation of glycerin 1% artificial tears extends tear film break-up time compared with systane lubricant eye drops. J Ocular Pharmacol Therap. 2012;28(5):473–478. doi:10.1089/jop.2011.0053
   PubMed Web of Science ®Google Scholar
• Jacobi C, Kruse FE, Cursiefen C. Prospective, randomized, controlled comparison of SYSTANE UD eye drops versus VISINE INTENSIV 1% EDO eye drops for the treatment of moderate dry eye. J Ocular Pharmacol Therap. 2012;28(6):598–603. doi:10.1089/jop.2012.0066
   PubMed Web of Science ®Google Scholar
• Jerkins G, Greiner JV, Tong L, et al. A comparison of efficacy and safety of two lipid-based lubricant eye drops for the management of evaporative dry eye disease. Clin Ophthalmol. 2020;14:1665–1673. doi:10.2147/opth.S256351
   Web of Science ®Google Scholar
• Khaireddin R, Schmidt KG. Comparative investigation of treatments for evaporative dry eye. Klin Monbl Augenheilkd. 2010;227(2):128–134. doi:10.1055/s-0028-1109686
   PubMed Web of Science ®Google Scholar
• Khanal S, Tomlinson A, Pearce EI, Simmons PA. Effect of an oil-in-water emulsion on the tear physiology of patients with mild to moderate dry eye. Cornea. 2007;26(2):175–181. doi:10.1097/ICO.0b013e31802b492d
   PubMed Web of Science ®Google Scholar
• Labetoulle M, Schmickler S, Galarreta D, et al. Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study. Clin Ophthalmol. 2018;12:2499–2508. doi:10.2147/opth.S177176
   Web of Science ®Google Scholar
• Laihia J, Jarvinen R, Wylegala E, Kaarniranta K. Disease aetiology-based design of multifunctional microemulsion eye drops for moderate or severe dry eye: a randomized, quadruple-masked and active-controlled clinical trial. Acta Ophthalmol. 2020;98(3):244–254. doi:10.1111/aos.14252
   Web of Science ®Google Scholar
• Nelson JD, Farris RL. Sodium hyaluronate and polyvinyl-alcohol artificial tear preparations - a comparison in patients with keratoconjunctivitis sicca. Arch Ophthalmol. 1988;106(4):484–487. doi:10.1001/archopht.1988.01060130530029
   Google Scholar
• Safarzadeh M, Azizzadeh P, Akbarshahi P. Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulose-dextran-containing eyedrops. J Optom. 2017;10(4):258–264. doi:10.1016/j.optom.2016.11.002
   PubMedGoogle Scholar
• Szegedi S, Scheschy U, Schmidl D, et al. Effect of single instillation of two hyaluronic acid-based topical lubricants on tear film thickness in patients with dry eye syndrome. J Ocular Pharmacol Therap. 2018;34(9):605–611. doi:10.1089/jop.2018.0069
   Web of Science ®Google Scholar
• Tomlinson A, Madden LC, Simmons PA. Effectiveness of dry eye therapy under conditions of environmental stress. Curr Eye Res. 2013;38(2):229–236. doi:10.3109/02713683.2012.757323
   PubMed Web of Science ®Google Scholar
• van Setten GB, Baudouin C, Horwath-Winter J, et al. The HYLAN M study: efficacy of 0.15% high molecular weight hyaluronan fluid in the treatment of severe dry eye disease in a multicenter randomized trial. J Clin Med. 2020;9(11):3536. doi:10.3390/jcm9113536
   Web of Science ®Google Scholar
• Waduthantri S, Yong SS, Tan CH, Htoon HM, Tong L. Lubricant with gelling agent in treating dry eye in adult Chinese patients. Optomet Vision Sci. 2012;89(11):1647–1653. doi:10.1097/OPX.0b013e31826cfc41
   PubMed Web of Science ®Google Scholar
• Wang TJ, Wang IJ, Ho JD, Chou HC, Lin SY, Huang MC. Comparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority study. Clin Ther. 2010;32(1):44–52. doi:10.1016/j.clinthera.2010.01.024
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG and Tetzlaff J, et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339(jul21 1), b2700–b2700. 10.1136/bmj.b2700
   PubMed Web of Science ®Google Scholar